<DOC>
	<DOCNO>NCT02109484</DOCNO>
	<brief_summary>This study parenteral rotavirus vaccine ( P2-VP8 subunit rotavirus vaccine ) . The study examine safety immunogenicity vaccine first healthy South African toddler . If safety profile deem appropriate , study continue explore safety immunogenicity vaccine healthy South African infant . The primary safety hypothesis P2-VP8 subunit rotavirus vaccine safe well-tolerated healthy toddler infant . The primary immunogenicity hypothesis P2-VP8 subunit rotavirus vaccine immunogenic infant participant induce immune response least 80 % participant least one study group .</brief_summary>
	<brief_title>Phase I/II Descending Age Study P2VP8 Subunit Parenteral Rotavirus Vaccine Healthy Toddlers Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy infants/toddlers establish medical history clinical examination enter study age : toddler cohort : &gt; = 2 &lt; 3 year old time enrollment infant cohort : &gt; = 6 &lt; 8 week time enrollment parental ability willingness provide inform consent parental intention remain area child study period . Presence fever day enrollment Acute disease time enrollment Concurrent participation another clinical trial throughout entire timeframe study Presence malnutrition systemic disorder ( cardiovascular , pulmonary , hepatic , renal , gastrointestinal , hematological , endocrine , immunological , dermatological , neurological , cancer autoimmune disease ) determine medical history and/or physical examination would compromise participant 's health likely result nonconformance protocol For infant cohort , history premature birth ( &lt; 37 week gestation ) History congenital abdominal disorder , intussusception , abdominal surgery Known suspect impairment immunological function base medical history physical examination For infant cohort , prior receipt rotavirus vaccine A known sensitivity allergy component study vaccine History anaphylactic reaction Major congenital genetic defect Participant 's parent able , available willing accept active weekly followup study staff Has receive immunoglobulin therapy and/or blood product since birth plan administration study period History chronic administration ( defined 14 day ) immunosuppressant medication , include corticosteroid . Infants inhale topical steroid may permit participate study Any medical condition parents/infant , judgment investigator , would interfere serf contraindication protocol adherence participant 's parent ' ability give inform consent HIV infection For toddler , assess HIV ELISA For infant , assess PCR , mother know negative ( negative test result 24 week gestation screening )</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>